Exagen (XGN) Invested Capital (2022 - 2026)

Exagen (XGN) has 5 years of Invested Capital data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Invested Capital rose 2.56% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 143.03% YoY) and the FY2025 annual result came in at $3.1 million, up 631.68% from the prior year.
• Invested Capital slipped to $2.6 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $3.1 million in Q4 2025 to a low of $190000.0 in Q4 2022.
• A 5-year average of $1.0 million and a median of $423000.0 in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2025 — Invested Capital soared 845.9% — and 2026, when it increased 2.56%.
• Tracing XGN's Invested Capital over 5 years: stood at $190000.0 in 2022, then jumped by 38.95% to $264000.0 in 2023, then jumped by 60.23% to $423000.0 in 2024, then surged by 631.68% to $3.1 million in 2025, then declined by 15.99% to $2.6 million in 2026.
• The last three Invested Capital figures came in at $2.6 million (Q1 2026), $3.1 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.